Two RZV Doses Effective Against Herpes Zoster, PHN In Patients Aged 50 Years And Older, Study Finds

Infectious Disease Advisor (8/5, Nye) reports a study found that “adults aged 50 years and older experience long-term, effective protection from herpes zoster (HZ) and postherpetic neuralgia (PHN) with 2 recombinant zoster vaccine (RZV) doses.” Researchers observed that “during a mean follow-up of 2.5 years, HZ occurred at a rate of 2.6 per 1000 person-years (PY) with 2 RZV doses compared with a rate of 9.2 per 1000 PY without vaccination. PHN occurred at rates of 0.1 and 0.5 per 1000 PY, respectively. The adjusted vaccine effectiveness (aVE) against HZ was 73.9% and against PHN was 83.7%.” The study was published in Clinical Infectious Diseases.